FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific Conference - read this article along with other careers information, tips and advice on BioSpace

Market Tree Research has added a new key research reports covering C DIFFICILE INFECTION DRUG market The study aims to provide global investors with a game changing decision making tool covering key fundamentals of the C DIFFICILE INFECTION DRUG market ...

London, UK | April 06, 2023 09:53 AM Eastern Daylight Time --p /Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) ch

A team of researchers from Harvard University has developed a suite of Escherichia coli Nissle 1917 (EcN), named PRObiotic type 3 secretion E. coli therapeutic (PROT3ECT), engineered to secrete a TNF-α nanobody directly into the gut to reduce inflammation in a chemically induced inflammatory bowel disease (IBD) mouse model.

Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) said data from a study on one of its lead assets has been peer-reviewed and published in Microbiology Spectrum. A...

Researchers have succeeded in developing an E. coli-based 'smart microbe' that secretes therapeutic payloads, including antibodies, into the gut. The genetically modified beneficial strain of bacteria blocks intestinal inflammation in a preclinical model of inflammatory bowel disease and has the potential to treat intestinal-based diseases.

A new study by researchers at Intermountain Health and Stanford University found that overprescribing and inappropriate prescribing of antibiotics is not only leading to antibiotic resistance, but also causing significant patient harm. Dr. Harris Carmichael, lead investigator of the study and a hospitalist at Intermountain Health, said the study, published in the Journal of Internal […]

Seres Therapeutics’ SER-109 has faced more setbacks than most drugs, but the biotech has kept the faith and is now tantalizingly close to possibly seeing its candidate

Vanderbilt has received an NIH grant to launch the Vanderbilt Antibody and Antigen Discovery for Clostridioides difficile Vaccines, or VANDy-CdV.

A new study has identified a compound that prevents C. diff infection. Researchers are now using this compound to develop new drug candidates that might eventually offer a way to prevent serious C. diff infections.

A bile salt analog prevented Clostridioides difficile infection (CDI) in mice, pointing to a potential way to minimize the impact of a bacterium that kills 20,000 people a year.

The signaling pathways and networks regulating expression of chondroitin sulfate proteoglycan 4 (CSPG4), a cancer-related protein that serves as a receptor for Clostridiodes difficile TcdB, are poorly defined. In this study, TcdB-resistant/CSPG4-negative HeLa cells were generated by exposure to incr …

Researchers at the University of Nevada, Las Vegas have identified a compound that prevents gastrointestinal infections from multiple strains of Chlostridiodes difficile (C. diff)—including those that can cause serious illness—and are now using the compound to develop drugs that could eventually prevent serious C. diff infections.

Researchers have identified a compound that prevents C. diff infection caused by multiple strains of the bacterium and are using it to develop new drug candidates that target the disease.

Could Your Liver Help Prevent C. Diff Infection? Breakthrough Research Offers Hope To Prevent C. Diff Infections Before They Start Researchers have made

Bacterial flagella are involved in infection through their roles in host cell adhesion, cell invasion, auto-agglutination, colonization, the formation of biofilms, and the regulation and secretion of nonflagellar bacterial proteins that are involved in the virulence process. In this study, we constr …

Mass General Brigham researchers at two hospitals found the metabolic strategies C. difficile uses to rapidly colonize the gut and identified ways to combat the disease

This research represents a significant step for better elucidating the interaction between drugs and the gut microbiome:https://t.co/oE2z0BpxBm— GutMicrobiota Health (@GMFHx) March 14, 2023

A team of investigators has identified metabolic strategies used by Clostridioides difficile to rapidly colonize the gut. The findings identify methods to better prevent and treat the most common cause of antibiotic-associated diarrhea and healthcare-acquired infections (HAIs). The team's approach has implications for understanding broader aspects of microbial metabolism, including responses to antibiotics, and production of important metabolites.

Background Postoperative prophylactic antibiotic usage for endoscopic skull base surgery varies based on the institution as evidence-based guidelines are lacking. The purpose of this study is to determine whether discontinuing postoperative prophylactic antibiotics in endoscopic endonasal cas …

This secondary analysis of a randomized clinical trial examines the association of SER-109 with health-related quality of life in 182 patients with recurrent Clostridioides difficile infection in the US and Canada.

Researchers investigated the tolerability and safety of a microbiome therapy called SER-109 to treat recurrent infections of Clostridioides difficile in adults.

Use of the investigational microbiome therapeutic SER-109 resulted in rapid and steady improvement in disease-specific quality of life for patients with recurrent Clostridioides difficile infection, according to data in JAMA Network Open.“C. diff infection is associated with poor quality of life (QOL), but improvement in QOL has never been demonstrated in randomized controlled